BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38599542)

  • 21. Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer.
    Ji F; Wang Y; Qiu L; Li S; Zhu J; Liang Z; Wan Y; Di W
    Int J Oncol; 2013 May; 42(5):1578-88. PubMed ID: 23545606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer.
    Ge X; Liu X; Lin F; Li P; Liu K; Geng R; Dai C; Lin Y; Tang W; Wu Z; Chang J; Lu J; Li J
    Oncotarget; 2016 Apr; 7(17):24466-82. PubMed ID: 27016414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.
    Gomez-Roman N; Sahasrabudhe NM; McGregor F; Chalmers AJ; Cassidy J; Plumb J
    Oncotarget; 2016 Apr; 7(16):22650-64. PubMed ID: 26967059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WNK1 Enhances Migration and Invasion in Breast Cancer Models.
    Jaykumar AB; Jung JU; Parida PK; Dang TT; Wichaidit C; Kannangara AR; Earnest S; Goldsmith EJ; Pearson GW; Malladi S; Cobb MH
    Mol Cancer Ther; 2021 Oct; 20(10):1800-1808. PubMed ID: 34253593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
    Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
    Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
    Sun H; Wang H; Wang X; Aoki Y; Wang X; Yang Y; Cheng X; Wang Z; Wang X
    Theranostics; 2020; 10(15):6928-6945. PubMed ID: 32550913
    [No Abstract]   [Full Text] [Related]  

  • 31. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer.
    He C; Wang L; Zhang J; Xu H
    Mol Cancer; 2017 Feb; 16(1):35. PubMed ID: 28173803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long non-coding RNA (lncRNA) five prime to Xist (FTX) promotes retinoblastoma progression by regulating the microRNA-320a/with-no-lysine kinases 1 (WNK1) axis.
    Wang X; Su Y; Yin C
    Bioengineered; 2021 Dec; 12(2):11622-11633. PubMed ID: 34720057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote glycolysis in hepatocellular carcinoma.
    Xu Z; Wu Y; Yang M; Wei H; Pu J
    Exp Cell Res; 2023 May; 426(1):113513. PubMed ID: 36780970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway.
    Wang Y; Ma J; Shen H; Wang C; Sun Y; Howell SB; Lin X
    Oncol Rep; 2014 Nov; 32(5):2150-8. PubMed ID: 25174950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PHF6 recruits BPTF to promote HIF-dependent pathway and progression in YAP-high breast cancer.
    Gao S; Zhang W; Ma J; Ni X
    J Transl Med; 2023 Mar; 21(1):220. PubMed ID: 36967443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation.
    Chen LY; Wang L; Ren YX; Pang Z; Liu Y; Sun XD; Tu J; Zhi Z; Qin Y; Sun LN; Li JM
    Mol Cancer; 2020 Nov; 19(1):164. PubMed ID: 33225938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
    Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
    Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through CREB1.
    Cao Y; Li J; Du Y; Sun Y; Liu L; Fang H; Liang Y; Mao S
    FASEB J; 2023 Dec; 37(12):e23288. PubMed ID: 37997502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.